Drug Profile
Research programme: lysosomal disorder therapeutics - Targeted Cell Therapies
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Targeted Cell Therapies
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Lysosomal storage diseases
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Lysosomal storage diseases in USA (PO)
- 13 Jul 2016 Research programme: lysosomal disorder therapeutics - Targeted Cell Therapies is available for licensing as of 13 Jul 2016. http://www.targetedcelltherapies.us/
- 13 Jul 2016 Early research in Lysosomal storage diseases in USA (PO)